Exclusive Summary

• Bromhexine Hydrochloride Tablets are a WHO essential medicine and Class A medical insurance drug, globally used for respiratory diseases with stable and substantial market demand.
• Original patent expired years ago, leading to a mature global generic market with fierce competition but continuous demand, especially in developing countries.
• The product has passed consistency evaluation and self-produces APIs, ensuring quality and cost advantages, making it internationally competitive.
• It holds a solid clinical position, widely recommended for mucolysis, with good safety profile for both children and adults.
• Potential markets include distribution in developing countries and seeking partnerships with existing brand owners in mature markets to fulfill supply chain or price advantage needs.

Asset Materials

Contact Us for Full Materials